Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells

Cancer Immunology, Immunotherapy

Volumn 50, Issue 7, 2001, Pages 382-390

  Ragnarsson, Lotten ^a   Strñmberg, Thomas ^a   Wijdenes, John ^b   Tñtterman, Thomas H ^a   Weigelt, Cecilia ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Diaclone   (France)

Author keywords

CTL; Immunotherapy; Multiple myeloma; Superantigen; Syndecan 1

Indexed keywords

CHROMIUM 51; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PROTEIN A; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN; SYNDECAN 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PLASMA CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ENTEROTOXINS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; PROTEOGLYCANS; SUPERANTIGENS; SYNDECAN-1; SYNDECANS; T-LYMPHOCYTES;

EID: 0034852598     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620100211     Document Type: Article

References (71)

1. Superantigen engineering
2. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A
3. Multiple myeloma: The biology of malignant plasma cells
4. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
5. Multiple myeloma
6. + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain
7. Distribution of T cell signalling molecules in human myeloma
8. The prognostic significance of T cells receptor beta gene rearrangements and idiotype-reactive T cell in multiple myeloma
9. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1
10. Syndecans: Multifunctional cell-surface co-receptors
11. Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin 6 fusion protein
12. The Mil5 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens
13. Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma
14. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
15. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma
16. Long-term cultivation of plasma cell leukemia cells and autologous lymphoblasts (LCL) in vitro: A comparative study
17. + T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies
18. Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins
19. Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies
20. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma
21. Modulated glycosylation of proteoglycans during differentiation of human B lymphocytes
22. Activation of transcription factor NF-kB in peripheral blood T cells from multiple myeloma patients is impaired and may contribute to their increased susceptibility to activation-induced apoptosis
23. Production of TNF-α and TNF-β by staphylococcal enterotoxin A activated human T cells
24. + cells and apoptosis suppress T-cell functions in multiple myeloma
25. Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells
26. Antibody-directed superantigen-mediated T cell killing of myeloid leukaemic cell line cells
27. Antibodies are capable of directing superantigen-mediated T-cell killing of chronic B lymphocytic leukemia cells
28. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies
29. Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma
30. Anti-B4-blocked ricin: A phase II trial of 7 day continuous infusion in patients with multiple myeloma
31. Multiple myeloma: Increasing evidence for a multistep transformation process
32. Characterization of a new IgG1 myeloma plasma cell line (EJM): A further tool in the investigation of the biology of multiple myeloma
33. Identification of novel and specific antigens of human plasma cells by mAb
34. Immunotherapy of multiple myeloma
35. Two new IgAl-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2
36. Establishment and phenotypic characterization of three new human myeloma cell lines (U-1957, U-1958, and U-1996)
37. Increase in interleukin-6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop
38. Human plasmacytoma with an unusual karyotype growing in vitro and producing light-chain immunoglobulin
39. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
40. Paracrine but not autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
41. Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma
42. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
43. Antibody therapy for treatment of multiple myeloma
44. Dysregulated Fas and bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients
45. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy
46. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma
47. + T cells in patients with multiple myeloma and paraproteinemia
48. Established immunoglobulin producing myeloma (IgE)
49. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells
50. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24
51. Interferongamma in multiple myeloma
52. The human myeloma cell line LP-i: A versatile model in which to study early plasma-cell differentiation and c-myc activation
53. Adhesion molecules on human myeloma cells: Significant changes in expression related to malignancy, tumor spreading, and immortalization
54. Gamma-Interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro
55. Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells
56. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells
57. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage
58. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen
59. B lymphocytes express and lose syndecan at specific stages of differentiation
60. Establishment and characterization of a CD5 positive, immunosuppressive human myeloma cell line
61. Serum syndecan-1: A new independent prognostic marker in multiple myeloma
62. gpl30 and c-kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells
63. + malignant plasma cells
64. + cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements
65. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
66. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy
67. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor
68. Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins
69. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells
70. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
71. + subsets